Clinical Trial Update: 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating the PET imaging agent 61Cu-NODAGA-LM3 for detecting neuroendocrine tumors; recruitment is currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• 61Cu-NODAGA-LM3 (61Cu-NODAGA-LM3)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Neuroendocrine Tumors | Phase 1, Phase 2 | Status: RECRUITING